Skip to Content
Global News Select

NRx Says Data Positive From Expanded Access Protocol in Covid-19; Shares Up

By Michael Dabaie


NRx Pharmaceuticals said data were positive from its Zyesami expanded access protocol in Covid-19, sending shares 14% higher to $20.50 premarket.

The expanded access protocol included 240 intensive care unit patients suffering critical Covid-19 with respiratory failure who had exhausted all approved therapies. The clinical stage pharmaceutical company said that overall, patients receiving at least one dose of Zyesami in addition to intensive care were alive at 28 days.

This EAP provided an opportunity for regional hospitals to offer Zyesami to its sickest patients, for whom no other options were available, and who couldn't enroll in a study due to additional risk factors. Enrollment in the EAP was offered to patients who were ineligible for the Zyesami phase 2b/3 clinical trial, and who had exhausted all approved therapies for Covid-19.

NRx said 56% of patients enrolled were already receiving mechanical ventilation, and 44% were receiving non-invasive forms of ventilation.

The company is providing the EAP data to the Food and Drug Administration as "real world data", in support of the findings from the Zyesami randomized controlled phase 2b/3 clinical trial.


Write to Michael Dabaie at


(END) Dow Jones Newswires

June 15, 2021 09:04 ET (13:04 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.